About US
Contact us
-
What competition? Vertex touts Trikafta's competitive edge on back of strong 2021Vertex finished out 2021 strong, smashing analyst’s sales expectations for the full year. Chalk it up to the company’s entrenched position in cystic fibrosis, where Vertex expects to maintain its lea2022/1/29
-
Pfizer in Texas showdown: Court hearing this week will decide if it can assist FDA in providing COVID documentsTexas federal judge Mark Pittman willconducta hearing on Friday to consider whether to allow Pfizer to participate in the redaction and release of information about the development of its COVID-19 va2022/1/27
-
Samsung buys Biogen out of biosimilar unit for $2.3B—not the whole Aduhelm headacheA recent report from Korea buzzed a Biogen takeover by Samsung. Turns out, Samsung is indeed buying something of Biogen’s, just not the entire company that’s saddled with the Alzheimer’s disease drug2022/1/27
-
Gilead's Veklury expands FDA nod to patients outside the hospital as oral version heads to trialGilead Sciences’ Veklury, the first FDA-approved COVID-19 treatment, has extended its reach to patients outside the hospital at a time when effective therapies against omicron are in high demand.2022/1/25
-
With omicron on the prowl, FDA extends inspection pause into FebruaryThe pandemic continues to drag on the FDA’s inspection plans. Now, the regulator is prolonging an intermission that kicked off just before the new year and was pegged to conclude last week.2022/1/25
-
Biogen CEO Vounatsos summons support to fight Aduhelm's paralyzing coverage decisionBiogen's take on the Centers for Medicare & Medicaid Services' (CMS') stifling coverage proposal for Alzheimer's disease drug Aduhelm? "Strong disagreement," CEO Michel Vounatsos said at the top2022/1/18
-
US faces 'critical moment' in pricing reform that 'won't come again,' nonprofit founder says after tallying 554 new hikesWith 2021 over, the pharmaceutical industry kicked off the New Year with one of its favorite pastimes: raising the prices on hundreds of branded meds. Public and political scrutiny didn’t stop many o2022/1/18
-
JPM 2022: Bluebird bio hopes for clear skies ahead as it gears up for trio of gene therapy launchesAfter a false start in Europe, bluebird bio is determined to give its trio of gene therapies a better shot in the U.S. Bluebird is readying the commercial nest ahead of a May decision on2022/1/14
-
JPM 2022: J&J, Legend hope to avoid supply challenges that have ailed Bristol Myers' Abecma as cilta-cel nears FDA nodLegend Biotech is prepping its Johnson & Johnson-partnered, “paradigm shifting” CAR-T multiple myeloma treatment cilta-cel for launch with a global manufacturing operation, which CEO Ying Huang,2022/1/14
-
JPM 2022: How Novavax plans to be a COVID-19 vaccine force in 2022Could 2022 be the year of the Novavax vaccine? Since the COVID-19 pandemic’s early days, the Gaithersburg, Maryland-based biotech has been plugging away on its shot, turning out impressive data but s2022/1/12